NCT06347497

Zonisamide Versus Topiramate in Migraine

Name: Clinical Trial NCT06347497
Creator: Kafrelsheikh University
Keywords: Migraine, Zonisamide 50 MG, Phase 3, drug, clinical trial, Egypt

Safety and Efficacy of Zonisamide Versus Topiramate in Migraine

Kafrelsheikh University·Phase 3·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Migraine
Drug/Device/Intervention: Zonisamide 50 MG
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Kafrelsheikh University
Location: Kafr Ash Shaykh, Egypt

Timeline & enrollment

Phase: Phase 3
Start date: Apr 01, 2024
End date: May 01, 2025
Enrollment: 600 participants

Primary outcome

The change in migraine days per 28 days

Summary

Investigators aim to compare the effect of zonisamide versus topiramate in migraine by assessing the absolute reduction in MMD in each group, the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency

ICD-10 classifications

MigraineOther migraineMigraine, unspecifiedComplicated migraineHeadache

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06347497
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06347497 through Pure Global AI's free database. This Phase 3 trial is sponsored by Kafrelsheikh University and is currently Recruiting. The study focuses on Migraine. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.